RUTI (Mycobacterium tuberculosis cell wall nanofragmanets suspension) / Teodoro Garcia - LARVOL DELTA

RUTIVAC-1 study: A randomized, double-blind, placebo-controlled phase I trial to evaluate the immunomodulatory effect of RUTI in individuals with high-risk non-muscle-invasive bladder cancer treated with intravesical BCG (ESMO 2024) - P1 | "RUTI® vaccination before intravesical BCG treatment in high-risk NMIBC pts is safe, very well tolerated, and significantly impacts immune response. This modulation might be associated with the extended disease-free survival seen in the RUTI® vaccinated pts."

Clinical • Immunomodulating • IO biomarker • P1 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • CD4 • CD69 • CD8 • IL2RA • ISG20 • TNFRSF9

A heterologous prime-boost strategy using RUTI vaccine to improve the BCG response in non–muscle-invasive bladder cancer patients (RUTIVAC-1 trial). (ASCO-GU 2025) - P1 | "RUTI vaccination prior to intravesical BCG treatment in NMIBC patients is safe and effectively modulates the BCG-induced immune response, promoting a more balanced effective/suppressive response. This novel approach has the potential to significantly improve clinical outcomes in the management of NMIBC."

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • CD27 • CD4 • CD69 • CD8 • IFNG • IL2 • IL2RA • ISG20 • TNFA • TNFRSF9

Antibiotic residues and antimicrobial resistance patterns of bacteria isolated from beef at Ruti Rufura Slaughterhouse, southwestern Uganda. (PubMed, Front Microbiol) - "Among 75 viable isolates, resistance was highest to ampicillin (97.3%), chloramphenicol (86.7%), tetracycline (82.7%), ceftriaxone (57.3%), and ciprofloxacin (54.7%), while gentamicin showed the highest susceptibility (86.7%). Beef marketed in southwestern Uganda frequently contains antimicrobial residues and antimicrobial-resistant bacteria, posing a potential food safety risk. Strengthened antimicrobial stewardship, enforcement of withdrawal periods, and integrated surveillance of antimicrobial residues and resistance in foods of animal origin are needed to support One Health efforts against antimicrobial resistance."

Journal

Efficacy of RUTI® immunotherapy against active tuberculosis in a mouse model challenges the Koch phenomenon. (PubMed, Front Tuberc) - "These data show for the first time the safety of immunotherapy with Mtb antigens in an active TB model, adding efficacy to SOC. This encourages the beginning of clinical studies to evaluate the safety and efficacy of RUTI® in TB patients to improve their health, reduce its potential infectiousness, and reduce the length of treatment."

Journal • Preclinical • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Advances in development of tuberculosis vaccines and preventive drug therapies: current pipeline, evidence, and access. (PubMed, Lancet Microbe) - "Platforms include live-attenuated mycobacterial vaccines (eg, MTBVAC), recombinant BCG-derived approaches (eg, VPM1002), protein-adjuvant subunit vaccines (eg, M72/AS01E), viral-vectored candidates (eg, AdHu5Ag85A, ChAdOx1.85A, and TB/FLU-04L), and inactivated whole-cell strategies (eg, DAR-901, RUTI, and Immuvac [MIP])...For contacts of multidrug-resistant or rifampicin-resistant tuberculosis, randomised trials and pooled analyses support 6 months of daily levofloxacin to reduce incident multidrug-resistant tuberculosis. Bedaquiline-containing preventive regimens and shorter fluoroquinolone-based combinations are under clinical evaluation, but definitive phase 3 efficacy data are not yet available. The expansion of the vaccine pipeline alongside improved short-course preventive regimens offers a credible opportunity to accelerate tuberculosis incidence decline, although translation into population-level impact will depend on shown efficacy, sustained financing, reliable..."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

RJ-RTV-01: A study to check whether adding RUTI to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the bodys defenses, with participants randomly receiving RUTI or a look-alike treatment. (clinicaltrialsregister.eu) - P1 | N=44 | Not yet recruiting | Sponsor: Laboratorio Reig Jofre S.A.

New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Reply to the Harry Herr’s Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedreño-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. (PubMed, Eur Urol) - No abstract available

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Re: Oscar Buisan, Pol Servian, Sonia Pedreño-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. (PubMed, Eur Urol) - No abstract available

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

CONSTAN-ARG: Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis (clinicaltrials.gov) - P2 | N=41 | Completed | Sponsor: Archivel Farma S.L. | Recruiting ➔ Completed

Trial completion • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB) (clinicaltrials.gov) - P2 | N=140 | Completed | Sponsor: Archivel Farma S.L. | Active, not recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Jun 2025 | Trial primary completion date: Mar 2025 ➔ Jun 2025

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. (PubMed, Eur Urol) - P1 | "The small sample size and baseline imbalances were the limitations. This phase 1 study supports the safety and immunogenicity of RUTI and provides encouraging data that warrant confirmation in larger trials to establish its potential clinical benefit as a novel therapeutic strategy."

Clinical • Journal • P1 data • Bladder Cancer • Genito-urinary Cancer • Infectious Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Tuberculosis • CD4 • CD8

Outstanding performance of p-Nitrophenol detection in alkaline solution by Bi2O3@Ru-TiO2 nanotube array composite electrodes. (PubMed, Anal Chim Acta) - "In this study, Ru-doped TiO2 nanotube arrays (Ru-TNA) were prepared by anodizing RuTi alloy sheets...The results demonstrate that different from common p-NP detection under neutral and acidic conditions, the Bi2O3@Ru-TNA electrode exhibits superior detection performance for p-NP in alkaline solution, with a linear range of 5-16000 μM, a sensitivity of 1.656 μA/μM·cm2, and a detection limit of 0.029 μM. Moreover, the electrode shows excellent selectivity, stability and high practical applicability."

Journal

Uropathogenic Escherichia coli (UPEC) that hides its identity: features of LC2 and EC73 strains from recurrent urinary tract infections. (PubMed, BMC Microbiol) - "The acquisition of virulence factors by horizontal transfer of accessory DNA, other than being the cause of transformation to pathogenic strains, is responsible for the genomic plasticity. Our findings suggest that a key role in RUTIs could be played by certain bacterial strains that may benefit from peculiar abilities to adapt and potentially develop reservoirs of persistence across different host environments."

Journal • Infectious Disease • Nephrology • CXCL8 • IL1B • IL6 • TNFA

RUTIVAC-1 Trial: RUTI vaccination as a heterologous prime–boost strategy to enhance BCG response in non muscle-invasive bladder cancer patients (EAU 2025) - No abstract available

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Microstructure and Phase Equilibria in BCC-B2 Nb-Ti-Ru Refractory Superalloys. (PubMed, Materials (Basel)) - "The B2 phase was found to be dominated by RuTi ordering, although considerable Nb solubility was observed up to 18 mol %...Although a two-phase microstructure of B2 precipitates in a BCC matrix was confirmed, the distribution of elements in the two phases resulted in a larger lattice misfit than expected. The results obtained in this investigation provide valuable information for the future development of RSAs utilizing Ru-based B2 strengthening precipitates."

Journal

Prophylaxis Options in Children With a History of Recurrent Urinary Tract Infections: A Systematic Review. (PubMed, Pediatrics) - "Cranberry products and nitrofurantoin lead to lower odds of symptomatic UTI episodes during prophylaxis compared with the control group and control, trimethoprim-sulfamethoxazole, or trimethoprim groups accordingly. Nitrofurantoin and cranberry products may decrease the incidence of symptomatic UTI episodes in pediatric patients with a history of RUTI. Future randomized control trials studying nonantibiotic prophylaxis options focusing on children with UTI recurrence and the risk for kidney scarring are needed to draw further conclusions."

Journal • Review • Glomerulonephritis • Infectious Disease • Nephrology • Pediatrics

Confining Flat Ru Islands into TiO2 Lattice with the Coexisting Ru-O-Ti and Ru-Ti Bonds for Ultra-Stable Hydrogen Evolution at Amperometric Current Density and Hydrogen Oxidation at High Potential. (PubMed, Adv Sci (Weinh)) - "The different electronegativity (χTi = 1.54 < χRu = 2.20 < χO = 3.44) can endow Ti sites in RuOTi bonds with more positive charge and stabilize Ru atoms of RuTi bonds with the low-valence...As expected, F-Ru@TiO2 shows a low HER overpotential of 74 mV at 1000 mA cm-2 and an ultrahigh mass activity of 3155 A gRu -1 for HOR. More importantly, F-Ru@TiO2 can tolerate the HER current density of 1000 mA cm-2 for 100 h and the high anodic potential for HOR up to 0.5 V versus RHE."

Journal

In-Depth Analysis of Diet Diary and Urine pH Measurements Improved Food Diet Reporting in Postmenopausal Women with RUTI. (PubMed, Womens Health Rep (New Rochelle)) - "The patients who reported drinking water had a significantly lower average urine pH than women who did not report drinking water (5.8 vs. 6.2; p = 0.026). In this cohort of postmenopausal women with RUTIs, in-depth analysis of our current FDR findings led to several actionable items, which will improve our current food diet self-reporting process by our patients."

Journal • Infectious Disease • Nephrology • Novel Coronavirus Disease • Women's Health

Prevalence and relevant factors of nocturia and its impact on sleep quality in Chinese university students. (PubMed, Sci Rep) - "Nocturia was common in Chinese university students and showed a negative impact on sleep and academic performance. Gender of female, history of enuresis, ease of waking up, urgency, frequency and RUTI were relevant factors for CRN."

Journal • Urinary Incontinence

Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB) (clinicaltrials.gov) - P2 | N=140 | Active, not recruiting | Sponsor: Archivel Farma S.L. | Recruiting ➔ Active, not recruiting | Phase classification: P2b ➔ P2 | Trial completion date: Nov 2025 ➔ Mar 2025 | Trial primary completion date: Nov 2025 ➔ Mar 2025

Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Amorphous-crystalline RuTi nanosheets enhancing OH species adsorption for efficient hydrogen oxidation catalysis. (PubMed, Chem Sci) - "Moreover, Ti doping can facilitate CO oxidation, leading to enhanced strength to CO poisoning. This work provides a strategy for enhancing alkaline HOR performance over Ru-based catalysts with heteroatom and heterointerface dual-engineering, which will attract immediate interest in chemistry, materials science and beyond."

Journal

CONSTAN-ARG: Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis (clinicaltrials.gov) - P2 | N=44 | Recruiting | Sponsor: Archivel Farma S.L. | Phase classification: P2b ➔ P2 | Trial completion date: Jul 2024 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Aug 2024

Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Development and feasibility of a telemedicine tool for patients with recurrent urinary tract infection: myRUTIcoach. (PubMed, Int Urogynecol J) - "This research describes the development and testing of myRUTIcoach for women with rUTI. Patients and HCPs reported high satisfaction and compliance with myRUTIcoach. However, adoption by the intended users is complex and influenced by all examined domains of the NASSS framework. We have already improved linkage to EHRs, but further optimization to meet patient needs may improve the effectiveness of this self-management tool for rUTI."

Journal • Infectious Disease • Nephrology

Comparative Genomic Analysis of ST131 Subclade C2 of ESBL-Producing E. coli Isolates from Patients with Recurrent and Sporadic Urinary Tract Infections. (PubMed, Microorganisms) - "Hence, additional factors that could aid in identifying bacterial properties contributing to the increased risk of RUTI due to ESBL-E. coli ST131 subclade C2 remains to be explored."

Journal • Infectious Disease • Nephrology

"Representando a los residentes de Can Ruti en el #HeartFailure2023 en Praga!" (,@Cardioresisgtip)

Cardiovascular • Congestive Heart Failure • Dyslipidemia • Heart Failure